4
Facility Specifications
Patholog y Patholog y
services are not
available; if
there is a way to
send patholog y
for review
when needed,
that should
occur (Basic
patholog y may
be available,
but diagnosis is
oen delayed
for more than
1 month; there
are no frozen
sections or
patholog y
consultations in
the region)
Pathology
services in
development
(ere are
basic patholog y
and frozen
section services;
consultations
are not readily
available)
Patholog y
services in
development
or not always
available
(Patholog y
services
including
frozen sections
are available;
tumor registry
and regular
multidisciplinary
conferences are
not consistently
available in the
region)
Pathology
available (Full
pathology
services
including
diagnosis,
consultation,
tumor
registry, and
multidisciplinary
conferences are
available)
Palliative
care
Palliative care
service is in
development;
basic palliative
care, including
pain and
symptom
management,
should be
provided
c
Pain and
symptom
management
available;
palliative care
service is in
development
Palliative care
service not
always available
Palliative care
service available
NOTE. It is the view of the American Society of Clinical Oncolog y that health care providers and
health care system decision makers should be guided by the recommendations for the highest stratum
of resources available. is guideline is intended to complement but not replace local guidelines. Bold
font indicates addition of a recommended action over a previous resource level (eg, in limited setting,
a bold action is one that was not recommended in basic).
a
Where medical facilities exist to take care of women who are at high risk for postoperative
complications.
b
Can be performed at some enhanced levels.
c
Palliative care is multifaceted and in some contexts can be provided concurrently with tumor-
directed therapy. Pain management and best supportive care are necessary but insufficient parts
of palliative care in all settings. Women with advanced cervical cancer with or without access to
tumor-directed therapy may have specific late-stage symptoms that require clinicians to perform or
offer urogenital-specific interventions. (See Special Commentary in full text Guideline).
Table 1. Treatment Capacity (cont'd)
Treatment Basic Limited Enhanced Maximal
